新天藥業(002873.SZ):擬4000萬元增資匯倫生物
格隆匯5月19日丨新天藥業(002873.SZ)公佈,公司為進一步加快公司在小分子化藥領域,包括抗腫瘤、心腦血管、呼吸及消化系統等疾病的仿製藥及創新藥領域的產業佈局,公司擬以自有資金對參股公司上海匯倫生物科技有限公司(原名“上海匯倫生命科技有限公司”,“匯倫生物”)進行增資,增資金額為4000萬元人民幣。
同時參與匯倫生物此次增資的其他主體分別為匯倫生物其他21名原股東按比例增資1661.55萬元人民幣,新引進南京泉言財務服務有限公司、貴陽市工業和信息化產業發展引導基金、施普蘭迪(北京)文化交流發展有限公司及其他5名自然人增資10338.45萬元人民幣,合計增資1.6億元人民幣。
此次增資前對匯倫生物的價值確定為匯倫生物前兩次增資完成後的全部股東權益價值10.9億元人民幣,此次增資完成後,匯倫生物的全部股東權益價值為12.5億元人民幣,公司對匯倫生物的投資總額為1.4億元人民幣,持有匯倫生物的股權比例將由9.1743%增加為11.2000%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.